Altered Akorn Test Data Cited as a Reason for Canceled Deal (2)

A former Akorn Inc. executive fired for giving phony data to drug regulators had a reputation within the company for submitting altered testing data, a lawyer said in a trial over a canceled buyout of the generic drugmaker.

A 2016 Akorn employee survey identified Mark Silverberg, the company’s ex-head of quality control, as someone who’d given Food and Drug Administration officials false test results as part of new-drug applications, Lewis Clayton, an attorney for Fresenius SE, said July 11.

That was more than a year before Akorn officials discovered Silverberg included phony test data in a request for FDA approval ...